Trial
NCT06185543
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
NeuroSense Therapeutics Ltd.
Collaborators
—
Condition
Alzheimer Disease
Intervention
PrimeC
Why stopped
Company will improve study desig
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-09